<DOC>
	<DOCNO>NCT02384837</DOCNO>
	<brief_summary>Although drug-eluting stent reduce rate restenosis late lumen loss compare bare metal stent , late stent thrombosis ( LST ) , life-threatening complication technology , emerge major concern . Researches indicate incomplete neointimal coverage stent strut important morphometric predictor LST . Pathological research show stenting disruption adjacent vulnerable plaque precipitate LST , Meanwhile , thin-cap fibroatheromas ( TCFA ) important predictor Major Adverse Cardiovascular . Therefore , hypothesis TCFA may impair intimal heal prone LST vivo . Optical coherence tomography ( OCT ) high-resolution ( &lt; 10 µm ) , catheter-based imaging modality capable investigate detailed coronary plaque morphology vivo.This study aim observe TCFA arise effect intimal healing stent strut lesion fractional flow reserve ( FFR ) ≤0.75 EXCEL biodegradable polymer-coated sirolimus-eluting stent implant 9 month follow : evaluate OCT FFR</brief_summary>
	<brief_title>Effect TCFA Neointimal Coverage After PCI 9 Months Follow-up</brief_title>
	<detailed_description>The primary end point Neointimal coverage 9 month stent implantation . Quality assurance plan address data validation registry procedure , include plan site monitoring audit . Data check compare data enter registry predefined rule range consistency data field registry . Source data verification ass accuracy , completeness , representativeness registry data compare data external data source ( e.g. , medical record , paper electronic case report form , interactive voice response system ) . Data dictionary contains detailed description variable used registry , include source variable , cod information use normal range relevant . Standard Operating Procedures address registry operation analysis activity , patient recruitment , data collection , data management , data analysis , report adverse event , change management . Sample size assessment specify number participant participant year necessary demonstrate effect .</detailed_description>
	<mesh_term>Chlorhexidine</mesh_term>
	<mesh_term>Chlorhexidine gluconate</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>18yrs≤Age≤75yrs stability unstable angina pectoris ( AP ) , chronic myocardial infarction ( OMI ) confirm myocardial ischemia De novo lesion native coronary artery ( Up two target lesion ) Lesion length ≤32mm RVD 2.5mm～4.0mm DS % ≥70 % visual test Coronary artery bypass surgery ( coronary artery bypass graft ) patient Subjects willing follow specify requirement followup To understand purpose trial willing sign inform consent accept clinical followup AMI within 7 day . CTO ( TIMI 0 ) , leave main lesion , ostial lesion transplant vascular lesion , bifurcation lesion ( reference collateral blood vessel diameter 2.5 mm high ) , stent restenosis lesion deal three pathological change ; Severe calcify lesion unable predilate . The distortion stent hamper lesion . NYHA≥Ⅲ LVEF＜40 % . Prior PCI within 1 year . Pregnancy lactation , plan pregnancy lactation . Subjects bleed tendency blood coagulation dysfunction PCI contraindication , anticoagulant therapy taboo ca n't continue take DAPT least 1 year . There diseases ( cancer , malignant tumor , congestive heart failure , organ transplantation candidate ) abuse history ( alcohol cocaine heroin , etc . ) , scheme compliance poor , interference relate data explanation limited life ( &lt; 1 year ) . To aspirin heparin clopidogrel cobalt chromium alloy rapamycin PLA polymer contrast agent one allergy . Serious liver kidney function complete subject ( ALT AST three time great upper limit normal ) . Before enrol participate clinical trial reach primary endpoint . Noncompliant subject could finish trial accordance requirement subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>national Cather Lad</keyword>
	<keyword>Interventional Imaging Training Base</keyword>
</DOC>